What did Promisia Healthcare Limited announce?

Promisia Healthcare Limited (NZX: PHL) filed “Annual Shareholders Meeting 2026” with NZX on 13 August 2026, as an agm announcement.

From the announcement:“Dear Shareholder Please find enclosed notice of Promisia Healthcare Limited’s Annual Shareholders’ Meeting which will be held at Duncan Cotterill, 148 Victoria Street, Christchurch on Thursday, 27 August 2026 starting at 3pm.”
When was it filed?
13 August 2026
Where is the original?
NZX announcement
Promisia Healthcare Limited logo

Annual Shareholders Meeting 2026

AGM13 August 2026PHLHealthcare

Dear Shareholder
Please find enclosed notice of Promisia Healthcare Limited’s Annual Shareholders’ Meeting which

will be held at Duncan Cotterill, 148 Victoria Street, Christchurch on Thursday, 27 August 2026

starting at 3pm. If you cannot attend in person, the meeting will be streamed and can be viewed at

this link: Microsoft Teams Meeting.

In addition to usual annual meeting business and a request for shareholders to consider approving

an increase to the Director fee pool, shareholders will be invited to discuss and then vote on a

proposed acquisition by Promisia.

Background

As announced to the market on 6 August 2026, Promisia has entered a conditional agreement to

acquire the Chatswood Retirement Village (Chatswood) for a purchase price of $25 million (the

Acquisition).

Chatswood is in Opawa, Christchurch and located in close proximity to Promisia’s existing care

facility in East Christchurch, Aldwins House. Together, they provide Promisia two of East

Christchurch’s largest care facilities and create a broader integrated offering across rest home,

hospital-level care, care suites, serviced apartments and ORA-based retirement living.

Chatswood comprises an integrated care facility and retirement village with 100 operational beds

and units, including 29 care beds, 42 care suites and 29 serviced apartments. Occupancy across

those operational beds and units as at 30 June 2026 was c.95%.

The Acquisition is a significant growth initiative for Promisia and is consistent with its stated strategy

of building regional scale through strategically located acquisitions, strengthening local recognition

and offering residents a broader range of high-quality care and accommodation options.

Acquisition terms

The purchase price for the Acquisition is $25 million, comprised of:

• $24 million cash payable on completion;

• An issue of up to 1 million fully paid ordinary shares in Promisia at an issue price of $0.50 per

share (Consideration Shares); and

• An issue of 1 million convertible notes, each with a face value of $0.50 per note, convertible

into fully paid ordinary shares in Promisia (Convertible Notes).


The cash component of the purchase price will be funded through cash on hand and debt financing.

The Acquisition is scheduled to settle on 1 October 2026. Further information on the transaction

structure can be found in the explanatory notes in the enclosed notice of meeting.

Please note that while the issue price per share is at a discount to the prevailing market price, it

reflects the agreed per share price when negotiations to acquire Chatswood commenced.

Promisia will debt fund the Acquisition with a new funding line from Bank of New Zealand. Promisia

has received committed terms from Bank of New Zealand for this funding and has satisfied all

conditions precedent to that funding that it can satisfy at this time. No capital raising is proposed to

finance the Acquisition.


2


Board recommendation

The Board (excluding Rhonda Sherriff, who is interested in the Acquisition) considers that the

Acquisition and all related transactions are in the best interests of Promisia and its shareholders and

recommends that shareholders vote in favour of the resolutions outlined in the notice of meeting.

The Board encourages you to read this notice of meeting and to exercise your right to vote.

The enclosed notice of meeting and Proxy Form contain detailed instructions on how shareholders

may lodge their vote or appoint a proxy to vote on their behalf if they are unable to attend the

meeting.

We look forward to seeing you at the meeting.

Issued by the Promisia non-interested Directors:



Tom Brankin Tony Mortenson

Director Director



Craig Percy Jill Hatchwell

Independent Director Independent Director



3


NOTICE OF ANNUAL MEETING

Notice is hereby given that the annual meeting of shareholders of Promisia Healthcare Limited

(Promisia) (Meeting) will be held at Duncan Cotterill, 148 Victoria Street, Christchurch on Thursday

27 August 2026, starting at 3pm.

Agenda

A. Chair’s introduction


B. Presentation to shareholders


C. Questions


D. Resolutions


Business

Resolutions

To consider and, if thought fit, to pass the following ordinary resolutions:

1. Auditor’s remuneration: To authorise the directors to fix the auditor’s remuneration for the

ensuing year.


2. Re-election of Craig Percy: That Craig Percy, who retires by rotation and is eligible for re-

election, be re-elected as a director of Promisia.


3. Re-election of Rhonda Sherriff: That Rhonda Sherriff, who retires by rotation and is eligible

for re-election, be re-elected as a director of Promisia.


4. Approval of Acquisition: That Promisia undertaking the Acquisition under Listing Rule 5.1.1

(major transaction), 5.2.1 (related party transaction) and Rule 4.2.1 (issue of new equity

securities) and on the terms more fully set out in the explanatory notes, is approved.


5. Directors’ fees: That under Listing Rule 2.11.1 (directors’ remuneration) the Board is

authorised to increase the aggregate maximum annual amount of fees that can be paid to

Directors from $200,000 approved in 2020 to $350,000, with such increase taking effect on 1

September 2026.


PROCEDURAL NOTES

Proxies

Any shareholder of Promisia who is entitled to attend and vote at the Meeting may appoint a proxy to

attend and vote on their behalf. A corporation which is a shareholder may appoint a representative to

attend the Meeting on its behalf in the same manner as it could appoint a proxy. A proxy does not need

to be a shareholder of Promisia. A proxy form can be returned by delivery, mail, email, or online (as set

out below).


4


Any Directors are prepared to act as proxy for shareholders. Where any Director is appointed as a

discretionary proxy and is not prohibited from voting, each of the Directors intends to vote in favour of

all the resolutions. Shareholders are encouraged to give express voting directions to any Director that

they appoint as their proxy. As the Chair (Rhonda Sherriff) is unable to vote on Resolution 4 and all

Directors are prohibited from voting on Resolution 5, any discretionary proxies given to the Chair will be

abstained from voting on Resolution 4 and any discretionary proxies given to any Director will be

abstained from voting on Resolution 5. Those voting restrictions are described further below and also

apply to Associated Persons (as defined in the NZX Listing Rules (Listing Rules)).

To appoint a proxy, you should complete and sign the enclosed proxy form and either return it by

delivery, mail or email to the share registrar of Promisia:

By delivery:

Promisia Healthcare Limited

c/- MUFG Pension & Market Services

Level 30, PWC Tower

15 Customs Street West

Auckland 1010


By email: meetings.nz@cm.mpms.mufg.com (please put the words ‘PHL Proxy Form’ in the subject line

for easy identification)

You may also lodge your proxy online at https://nz.investorcentre.mpms.mufg.com/voting/PHL . You

will need to enter your CSN/Holder Number and Authorisation Code (FIN) to securely complete your

proxy appointment. A shareholder will be taken to have signed the proxy form by lodging it in

accordance with the instructions on the website.

The completed proxy form must be received by MUFG Pension & Market Services no later than 48 hours

before the meeting, being 3pm on Tuesday, 25 August 2026. Online proxy appointments must be

completed by this time also. Registered shareholders at that time will be the only persons entitled to

vote at the Meeting and only the shares registered in those shareholders’ names at that time may be

voted at the Meeting.

Shareholder Questions

Shareholders attending the Meeting will be given the opportunity to raise questions.

Shareholders may also submit written questions on the bottom of the proxy form. The main themes will

be aggregated and responded to at the Meeting. Alternatively, written questions can be sent online at

https://nz.investorcentre.mpms.mufg.com/voting/PHL or by email to francisco.rf@promisia.co.nz.

Promisia reserves the right not to address questions that, in the Chair’s opinion, are not reasonable in

the context of an Annual Shareholders’ Meeting, or any written questions that are not received by 3pm

on Tuesday, 25 August 2026.

Ordinary Resolutions

All resolutions are ordinary resolutions. An ordinary resolution is a resolution passed by more than 50%

of the votes of those shareholders entitled to vote and voting on the resolutions in person or by proxy.

By mail:

Promisia Healthcare Limited

c/- MUFG Pension & Market Services

PO Box 91976

Auckland 1142


5


Voting Restrictions

Under Listing Rule 6.3.1, voting restrictions apply to Resolution 4 and to Resolution 5.

Rhonda Sherriff and her Associated Persons (as that term is defined in the Listing Rules) are excluded

from voting on Resolution 4 as Rhonda Sherriff is (through the Sherriff Interest) a vendor of Chatswood

and a party to the transactions described in Resolution 4.

All directors of Promisia and their respective Associated Persons are excluded from voting on Resolution

5 because the directors are the recipients of the directors’ fees for which approval is sought.

“Associated Person” includes persons or legal entities who are able to directly or indirectly, exert a

substantial degree of influence over the activities of another person or legal entity (or vice versa).

Promisia will disregard any votes cast on Resolution 4 or Resolution 5 by any person to whom the above

restriction applies. Any discretionary proxies given to persons disqualified from voting under the

requirements set out above will not be valid.

Annual Meeting Presentation and FY26 Annual Report

The Meeting presentation and voting results will be announced to the NZX Market following the

Meeting and published on the Company’s website at http://www.promisia.co.nz/investor-

centre/#investor-news.

A copy of Promisia’s FY26 Annual Report is available on the Company’s website at

http://www.promisia.co.nz/investor-centre/#reports-&-results.

To receive Promisia reports by email you can update your communication preferences by visiting the

MUFG Investor Centre at https://nz.investorcentre.mpms.mufg.com or email to

operations.nz@cm.mpms.mufg.com (Please use “PHL Report” as the subject line for easy identification).

Definitions

Capitalised terms not defined in this Notice have the same meaning as in the Listing Rules.

NZ RegCo No Objection

This Notice has been reviewed by NZX Regulation Limited (NZ RegCo). NZ RegCo has confirmed it has

no objection to this Notice but takes no responsibility for the contents of this Notice.








6


Explanatory Notes

Resolution 1: Auditors’ Remuneration

The Companies Act 1993 requires the Company to appoint an auditor and provides that the fees and

expenses of an auditor appointed at an annual meeting can be fixed in the manner determined at

that meeting. Section 207S of the Companies Act 1993 provides that the remuneration of the

auditor is to be fixed in such a manner as the Company determines at the meeting. The Board

proposes that, consistent with commercial practice, the auditor’s remuneration should be fixed by

the directors.

The resolution authorises the Board to fix the remuneration of William Buck Audit (NZ) Limited as

the Company’s auditor.

Resolution 2: Re-election of Craig Percy

Board Role: Independent, non-executive Director

Craig has had over 20 years’ experience in the aged care and retirement village sectors, in both New

Zealand and the United Kingdom. This includes holding the role of Chief Operating Officer at LifeCare

Residences in London and the role of General Manager at ElderCare New Zealand Limited, now part

of NZX-listed Oceania Healthcare. Craig was also previously involved in establishing the Greytown

Orchards retirement village in the Wairarapa.

For the purpose of Listing Rule 7.8.3, the Board considers Craig to be an independent director. The

Board considered all relevant factors, including those set out in Table 2.4 of the NZX Corporate

Governance Code (Code Factors), in determining Craig’s independence. Code Factor 1 was

applicable for the Board in this assessment because Craig served as an executive of the Company

between late 2024 and May 2025. Due to this, the Board also specifically considered whether

triggering Code Factor 1 meant that Craig had a Disqualifying Relationship under the Listing Rules

and could not be considered independent.

A Disqualifying Relationship is having any direct or indirect interest, position, association, or

relationship that could reasonably influence or be reasonably be perceived to influence, in a material

way, Craig’s capacity to bring an independent view to decisions, act in the bests of Promisia, or

represent the interests of shareholders generally, having regard to the Code Factors. The Board

formed the view that that Craig does not have a Disqualifying Relationship, and that it was

reasonable for Craig to return to independent director status as of 31 May 2026. In particular, the

Board did not consider that his service as an executive would influence his ability to bring an

independent view or act in the best interests of Promisia or its shareholders given that:

• His executive role was only for six months on a part time basis to support Promisia while the

Board recruited a permanent Chief Operating Officer;

• His role involved providing temporary operational leadership rather than longer term

strategic or financial decision making; and

• All statutory financial reporting covering the period in which he provided assistance has

been completed.


The Board unanimously supports the re-election of Craig.


7


Resolution 3: Re-election of Rhonda Sherriff

Board Role: Independent, non-executive Director, Chair of the Board

Rhonda has worked in the aged care sector for over 30 years in governance, senior leadership,

clinical, quality and operational management roles. Rhonda is currently a Board member of the New

Zealand Aged Care Association. Rhonda commenced her career as a registered nurse and regularly

consults to the industry providing support and advice to a number of industry providers.

For the purpose of Listing Rule 7.8.3, the Board considers Rhonda to be an independent director. The

Board considered all relevant factors, including the Code Factors, in determining Rhonda’s

independence and considers that none of the Code Factors apply to Rhonda. The Board does not

consider that completing the Acquisition, should Resolution 4 be approved, will result in Rhonda

losing her independence as no Code Factors will ostensibly apply to Rhonda, and there is no other

reason that causes Rhonda to have a Disqualifying Relationship.

The Board unanimously supports the re-election of Rhonda.

Resolution 4: Acquisition of Chatswood Retirement Village

Background

Promisia has entered into an agreement (Agreement) with the shareholders of Chatswood

Retirement Limited (CRL) and Chatswood Lifecare Limited (CLL) to purchase 100% of the shares on

issue in each of those companies. Together CRL and CLL own and operate Chatswood Retirement

Village (Chatswood). Under the Agreement the purchase price of Chatswood is $25 million (the

Acquisition). If the Acquisition is completed, Promisia will own and operate Chatswood through

owning all of the shares of CRL and CLL.

About Chatswood

Chatswood is located at 60 Hawford Road, Opawa, Christchurch, within close proximity to Aldwins

House, one of Promisia’s existing aged care facilities.

CRL owns the land and buildings comprising Chatswood and is the retirement village operator. CLL

manages the integrated village and care operations, providing rest home and hospital-level aged

care, together with assisted-living services, across the 29 care beds, 42 care suites and 29 serviced

apartments. Together, CLL and CRL comprise an integrated care facility and retirement village.

The shareholders of CLL and CRL (the Vendors) are Aged Care Trust Limited (the Ennor Interest) and

HC Trustees 2010 Limited, Rhonda Jane Sherriff and Peter John Sherriff (together, the Sherriff

Interest).

The Chatswood site comprises of a purpose built and integrated high needs aged care and

retirement village complex spanning 1.2643 hectares. CRL owns freehold title to the Chatswood

property, and the property is situated 4.5km from the Christchurch CBD. The property is permitted

for use as a retirement village and care facility and benefits from dual street access and close

proximity to local medical and community facilities.

The original rest home at Chatswood dates back to 1990 and is now obsolete following extensions

and redevelopment of the property. The extensions to the original rest home were completed across

five stages beginning in 2013, with the most recent stage completed in 2023. As a result of these


8


works, the accommodation available to Chatswood residents are primarily modern studio care suites

and studio and one- and two-bedroom serviced apartments.

There is further scope to develop the operations at Chatswood by re-developing the original rest

home wing and certain adjoining residential sites. Altogether, there is an estimated 2,600m

2

of

development land available, including land occupied by the original rest home wing and two

adjoining residential properties. While these development opportunities are part of the strategic

rationale behind the Acquisition, Promisia’s initial priority will be operational integration and any

development will be considered in the future as part of the Board’s broader capital allocation

decisions across the entire Promisia portfolio.


Related Party Involvement

The Sherriff Interest is associated with Rhonda Sherriff, the Chair of Promisia. When discussions first

commenced regarding the Acquisition the non-interested directors on the Promisia Board formed a

sub-committee (being Tony Mortenson, Tom Brankin, Jill Hatchwell and Craig Percy) to provide

governance oversight of the Acquisition process and the negotiation of the key commercial terms.

Operational and negotiation work on the Acquisition was otherwise led by Promisia’s executive

leadership team with external legal and valuation support. In the Board’s view, the Acquisition has

been negotiated and agreed on a commercial arm’s length basis.

Rhonda Sherriff did not participate in any Board deliberations, decisions or negotiations relating to

the Acquisition in her capacity as a Promisia director and recused herself from Board meetings at any

time that the Acquisition was discussed.


Rationale for the Acquisition

The Board considers that a Material Transaction with a Related Party is appropriate in this context,

as the Acquisition has clear strategic merit for Promisia. Since acquiring the Golden View and

Ripponburn facilities in Cromwell approximately two years ago, Promisia’s core focus has been on

lifting occupancy at its facilities and realising operational efficiencies across its facilities to create a

strong foundation for further growth by acquisition. A number of potential acquisitions have been

considered over this time and either disregarded (particularly due to location, local market

demographics or differing views on value) or remain under investigation. The non-interested

directors considered Chatswood a compelling opportunity to pursue given its strategic fit with the

existing portfolio, strong reputation for resident care and strong financial performance.

Acquiring Chatswood gives Promisia development optionality in a high demand market for aged

care, leveraging its operational platform to improve financial performance and care outcomes for

residents. Promisia’s strategy is to continue growing its portfolio of facilities and with its current

facilities performing strongly and an effective leadership team in place, the Board considers Promisia

is now well placed to take further growth steps by acquiring an asset that fits strongly within its

operating profile:

- Locality: Located near Aldwins House and Promisia’s national support office, creating a

stronger East Christchurch cluster and enabling group resources to support operational

performance at Chatswood.


9


- Complementary offering: Chatswood’s care suites, serviced apartments and ORA-based

retirement living complement Aldwins House’s care-only offering, allowing Promisia to serve

a broader range of residents within the same community.

- Demographics: The demographics of Christchurch indicate continued growth in demand for

aged care in the medium to long term.

- Development Opportunity: There is an opportunity to further develop the Chatswood

property to increase resident capacity in the future.

- Reputation: Promisia considers that Chatswood has a strong reputation for delivering high

quality care to residents and notes that Chatswood recently received a four-year

certification from the Ministry of Health, the highest certification period available under

New Zealand’s aged care certification framework.


Chatswood is a logical addition to Promisia’s existing portfolio of five residential care facilities and

three retirement villages. Along with regional clusters in Feilding (Ranfurly Manor and Nelson Street)

and Cromwell (Golden View and Ripponburn), Chatswood creates a third cluster in Christchurch and,

in particular, east Christchurch, alongside Aldwins House. Aldwins House is a care facility with

resthome and hospital beds only and accordingly Chatswood, with its retirement village operations,

adds to Promisia’s continuum of care offering in east Christchurch with the added benefit of being

located close to Promisia’s national support office which is also in east Christchurch. Shareholders

are encouraged to review Promisia’s FY26 Annual Report for further information on Promisia’s

strategy, Promisia’s existing portfolio of facilities and their recent performance.


Acquisition Terms

If the Acquisition goes unconditional, completion is agreed to occur on 1 October 2026 (Completion

Date). On the Completion Date Promisia will satisfy the purchase price in full and acquire the shares

in Chatswood and will become the sole owner and operator of Chatswood from that time.

As at the date of this Notice, the Acquisition is conditional on:

(a) Promisia shareholder approval as is being sought under Resolution 4;


(b) Promisia being satisfied that arrangements acceptable to Promisia have been put in place to

secure the ongoing employment of the employees it considers key to the ongoing operation

of the business following Completion;


(c) there being no material adverse change to the assets, land, or business of Chatswood up

until the Completion Date; and


(d) Promisia being satisfied that the vendors have taken all reasonable steps to ensure that a

Code Compliance Certificate will be issued under the Building Act for certain recent works

that were undertaken at Chatswood.


If any conditions are not satisfied the Acquisition may not proceed. The vendors will remain

responsible (and liable) for obtaining the code compliance certificate referred to under condition (f)

noted above following the Completion Date if it is not obtained by that time.


10


Each of the conditions (except for the material adverse change condition) is due to be satisfied by 31

August 2026 (the Condition Date). Accordingly, Promisia expects the Acquisition to otherwise be

unconditional no later than the Condition Date.

The sale and purchase agreement otherwise contains provisions considered customary for a

transaction of this nature such as business warranties, a tax indemnity and operating requirements

through until the Completion Date. Promisia’s due diligence investigations verified that Chatswood

has been very well run and operates at a high level of compliance in a highly regulated sector.

Purchase Price

The Purchase Price for Chatswood is NZ$25,000,000 (plus GST if any), subject to a customary

adjustment (Purchase Price). The Purchase Price will be satisfied as follows:

(a) NZ$24,000,000 payable in cash on the Completion Date. A deposit equal to 5% of the

purchase price will be payable once the sale and purchase agreement becomes

unconditional (other than in respect of the material adverse change condition);

(b) the issue of up to 1,000,000 fully paid ordinary shares in Promisia (the Consideration Shares)

to the Sherriff Interest at an issue price of NZ$0.50 per share (having a value of up to

NZ$500,000) on the terms of a subscription agreement (Subscription Agreement)

summarised below; and

(c) the issue of a convertible note with a principal amount of NZ$500,000 (the Convertible

Note) to the Ennor Interest on the terms of a convertible note agreement (Convertible Note

Agreement) summarised below.


The Subscription Agreement and the Convertible Note Agreement are the only material ancillary

agreements to the sale and purchase agreement. We summarise the key terms of each agreement

below.

Promisia may elect to satisfy all or any part of the Consideration Shares or the Convertible Note

component of the Purchase Price by paying the equivalent amount in cash at Completion, in which

case the number of Consideration Shares or amount of the Convertible Note will be reduced

accordingly.

The Convertible Note will bear interest at 0% per annum and matures 12 months after the

Completion Date. The Convertible Note is convertible into fully paid ordinary shares in Promisia at an

issue price of NZ$0.50 per share at any time during the term (in increments of NZ$50,000) at the

option of the Ennor Interest. To the extent not converted, the principal will be repayable in full at

maturity. The Convertible Note will be unsecured debt of Promisia ranking equally with all other

unsecured creditors.

The Consideration Shares will be issued to the Sherriff Interest at Completion, ranking equally with

all existing Promisia ordinary shares from allotment.

There are no escrow or trading restrictions applicable to the Consideration Shares or any shares

issued on conversion of the Convertible Note.

As part of approving the Acquisition under Resolution 4 shareholders are also being asked to

specifically approve the issue of the Consideration Shares and the Convertible Note for the purposes

of the Listing Rules.


11


Independent Valuation

After indicatively agreeing the Purchase Price for Chatswood (based on its historic financial

performance, previous valuations of Chatswood and the potential value of Chatswood within

Promisia), Promisia commissioned an independent valuation on Chatswood from CBRE Limited

(CBRE) dated 31 July 2026 (the CBRE Valuation). The purpose of the valuation was to validate the

negotiated purchase price and assist the Board in establishing a carrying value for Chatswood from

the Completion Date for Promisia’s financial statements.

The CBRE Valuation valued Chatswood at NZ$26.2 million, being NZ$1.2 million above the Purchase

Price. The value of Chatswood was broken down into three components:

• Operator’s interest: $16.15 million, representing 61.64% of the market value;

• Care Facility: $8.9 million, representing 33.97% of the market value; and

• Development Land: $1.115 million, representing 4.26% of the market value.


The key assumptions behind the CBRE Valuation are:

• ORA terms: future ORA sales adopt Promisia’s standard ORA terms;

• Discount rate and growth: a discount rate of 15% has been applied to projected cash flows.

Unit prices are assumed to grow at 1% in year one, increasing to 3 – 3.5% p.a from year five

onwards;

• Resident turnover: average occupancy period of 4.3 years for serviced apartment residents

and 2.9 years for care suite residents;

• Occupancy: long-term stabilised occupancy of 93.1% across 71 beds;

• Market conditions: the CBRE Valuation reflects market sentiment at 31 July 2026; and

• Other assumptions: included average sales prices, expense proportions, compliance with

the Retirement Villages Act 2003, the site being free from contamination, no significant

immediate capital expenditure required for the modern buildings, and transfer of the

Facility’s health certification on Completion.


The Board considers that the CBRE Valuation validates the Purchase Price and can be a reassurance

to shareholders that, despite the related party nature of the Acquisition, there is no inappropriate

transfer of value occurring. A letter from CBRE is appended to this Notice of Meeting summarising

their valuation of Chatswood for shareholder information and confirming CBRE’s independence. For

the purposes of CBRE’s letter, ‘Market Valuation’ is synonymous to Fair Value under NZ IFRS 13, and

can be explained as the price that would be received to sell Chatswood in an orderly transaction

between market participants as at 31 July 2026.

Issue of Equity Securities

The Non-Interested Directors initiated discussions with the Sherriff Interest and the Ennor Interest to

gauge their interest in a sale of Chatswood to Promisia in 2025 as they were aware that the Sherriff

Interest and Ennor Interest were amenable to (without actively seeking at that time) a sale

opportunity. The Vendors were open to a discussing a potential sale but were not highly motivated

sellers, Chatswood is a very well run and profitable business that the Vendors expressed to Promisia

a number of times that they would be content to continue to own. Discussions in late 2025 were

highly prospective and led only to general discussions around potential terms and the Vendors

providing Promisia with some preliminary due diligence information. Promisia was not positioned to

make a new acquisition when those discussions commenced. Instead, the Board and Management


12


were primarily focused on improving operational efficiencies at Promisia’s existing facilities,

consolidating and reducing funding costs and embedding an operating leadership team under

Promisia’s (then new) Chief Operating Officer, Graeme Dodd. This disciplined focus was a success as

demonstrated by a strong financial result, a significant valuation uplift across Promisia’s facilities and

a significant reduction in Promisia’s borrowing costs in the FY26 financial results.

In late January 2026, Promisia was well positioned. Having undertaken preliminary due diligence,

formal negotiations commenced and the Non-Interested Directors and senior management then

proposed, negotiated and in late April 2026 entered an indicative non-binding term sheet with the

Sherriff Interest and the Ennor Interest to acquire Chatswood.

As part of the Acquisition the Board sought that a modest equity component to the Purchase Price

was included to mitigate the level of borrowings Promisia would assume and to align the interests of

the Sherriff Interest and the Ennor Interest with Promisia’s shareholders. Following discussions over

the course of March and April 2026, Promisia proposed an issue price for the new shares at $0.50c

per share on 21 April 2026 (when Promisia’s shares were trading at $0.445c per share). The Vendors

accepted this offer, and the term sheet was signed, on 24 April 2026. The Board acknowledges that

the share price has since risen but this issue price formed part of the overall commercial

negotiations at that point in time and actually represented a premium to the then share price of the

Company.

Should all Consideration Shares be issued under the Subscription Agreement, and all shares be

issued on conversion of the Convertible Note, Promisia will issue 2 million Shares in aggregate in part

fulfilment of the Purchase Price. This represents 3.78% of all shares on issue at the date of this

Notice. A shareholder who currently holds 5% of the shares on issue in Promisia, will hold 4.82% of

the shares on issue in Promisia if both the Consideration Shares and all shares on conversion of the

Convertible Note are issued.

Financial Performance of Chatswood

The Acquisition is expected to be immediately accretive to Promisia’s underlying earnings and

operating free cash flow.

Based on Chatswood’s current operating performance and the latest financial information available,

on a standalone annualised basis Chatswood is expected to contribute circa:

• $7.0 million of care fee revenue;

• $1.5 million of deferred management fee income; and

• $2.5 million to $3.5 million of operating free cash flow, depending on the timing and level of

occupation right agreement resale activity.

Occupation right agreement resale activity can vary between financial periods and, accordingly, the

operating free cash flow generated by Chatswood will vary from year to year. The summary financial

performance of Chatswood in its last two financial years

1

is:



1

Taken from unaudited consolidated statement of financial performance for CRL and CLL for the periods

stated.


13



YE 31 March 2025 YE 31 March 2026

Total sales

$9,007,832 10,484,697

Operating surplus

$2,288,382 3,814,425

Other income

$37,601 22,158

Net profit

$2,225,914 3,750,489


Promisia has also identified opportunities to improve Chatswood’s financial performance over time

by applying its existing support office capabilities, operating scale and procurement arrangements.

Based on the final CBRE Valuation and the agreed Purchase Price, the Acquisition is expected to

increase Promisia’s net tangible assets per share by approximately 1.1 cents, or 1.0%, based on

Promisia’s net tangible assets per share of $1.09 as at 31 March 2026. This calculation assumes the

Consideration Shares are issued and the Convertible Note remains outstanding as debt.

Assuming all Promisia warrants on issue are exercised and the Convertible Note is converted into

Promisia shares, pro forma fully diluted net tangible assets per share would be approximately $0.89,

based on Promisia’s financial position as at 31 March 2026. This scenario would also result in

approximately $14.2 million of additional cash being introduced into Promisia through the exercise

of the warrants.

In the view of the non-interested directors, the Acquisition provides strong financial benefits for

Promisia and its shareholders, supported by the strategic rationale outlined above.

Purchase Price Funding

Promisia proposes to fund the Acquisitions through a mixture of:

• $20 million of new debt facilities with the Bank of New Zealand (BNZ); and

• Cash on hand.


The key terms of the new BNZ facilities are:

Facilities

Core Facility: A new $15 million customised average rate loan facility,

to sit alongside Promisia’s existing $31.07 million facility.

Bridge Facility: A new $5 million customised average rate loan facility.

Initial term Core Facility: Two year term.

Bridge Facility: Nine month term.

Interest rate In the process of being fixed through interest swaps. It is expected that

the weighted average interest rate across all facilities will range

between 5.6% and 5.9%.

Amortisation Both facilities are interest only for the duration of their Term.


14


Conditions precedent - Statutory supervisor approval of financing and security

arrangements.

- Approval of a registered valuation. This condition has been

satisfied by the CBRE Valuation.

Bank covenants Loan to Value Ratio (LVR): The aggregate borrowing limits for Promisia

with BNZ must not exceed 55% of the market value of Promisia’s

property assets (determined by annual valuations).

Financial Cover: Adjusted EBITDA is to be maintained at a minimum of

2.00x and from 31 December 2026, a minimum of 2.25x.

Security First mortgages over all properties owned by Promisia (subject to the

priority at law of the statutory supervisor interest).

Interlocking guarantee from all members of the Promisia group.


Promisia has received and executed a committed offer from BNZ for the above facilities, and will

draw them down at Completion.

Promisia’s internal forecasting is that following drawdown of the above facilities, Promisia will

comply with the BNZ covenants. Promisia anticipates that its LVR based on drawn bank facilities

immediately following the Completion Date will be approximately 42%.

The new facilities described above are in addition to Promisia’s existing debt facility, which we

summarise below:

Facility Core Facility: A $31.07 million customised average rate loan facility.


Maturity Date 13 December 2027

Covenants As set out for the new BNZ facilities above.

Security First mortgages over all properties owned by Promisia (subject to the

priority at law of the statutory supervisor interest).

Interlocking guarantee from all members of the Promisia group.


Promisia also owes monies to Rivercrest Cromwell Limited for the purchase of Golden View Village in

Cromwell. Promisia currently leases this village and is prepaying the purchase price ahead of final

settlement in August 2028. No interest or other financing costs are payable in respect of this

amount. From August 2024, Promisia was liable to pay:

• $8.64 million in 48 equal monthly instalments of $180,000; and

• A final payment of $4.71 million due in August 2028 (when Promisia will acquire

freehold title to Golden View Village).


15


All monthly instalments have been paid to Rivercrest Cromwell Limited when due and, given the

high level of equity that Promisia will hold in Golden View Village at the time of the final payment,

the Board has a reasonable expectation of drawing debt finance to fund the final payment.

As at 30 June 2026 Promisia held cash liquidity of approximately $4.7 million. Given its high

occupancy rates and positive operating cash flows, the Board considers that Promisia will have more

than sufficient cash on hand at the Completion Date to fund its cash contribution to the Purchase

Price.

Promisia’s currently has approximately 28.3 million $0.50 warrants on issue that expire in March

2027. Given their exercise price is at a discount to the prevailing market price of Promisia shares

($0.76 as at 13 August 2026) it is anticipated that a reasonable proportion of the warrants will be

exercised and provide Promisia with new capital by the warrant expiry date (24 March 2027). The

Board was mindful in pursuing the Acquisition to minimise dilution to shareholders given the

likelihood of new shares being issued and warrant exercise monies being received early next year.

Accordingly, it is anticipated that the bridge facility will be repaid with those warrant proceeds.

Based on Promisia’s current forecasts, the Bridge Facility can also be repaid from operating free cash

flow generated by the Group without reliance on warrant exercise proceeds. Warrant proceeds

would provide additional repayment capacity and accelerate the reduction in bank debt. Given

Promisia’s forecast cash generation and anticipated LVR headroom, the Board considers the risk of

being unable to repay the Bridge Facility at maturity to be low.

Shareholder Approval

Shareholder approval is required under Listing Rule 5.1.1(b) by way of an ordinary resolution. Listing

Rule 5.1.1(b) provides that, except with the prior approval by an ordinary resolution, Promisia may

not enter into any transaction or related series of transactions to acquire, sell, exchange, or

otherwise dispose of assets of Promisia in respect of which the gross value is in excess of 50% of the

Average Market Capitalisation of Promisia. The Purchase Price exceeds 50% of the Average Market

Capitalisation of Promisia as at 5 August 2026 (being the date of entry into the Acquisition and when

the announcement of Acquisition was released to shareholders on the NZX).

While the Listing Rules prescribe that this test is assessed against market capitalisation, shareholders

should note that the Purchase Price represents only 12.5% of Promisia’s total assets and Promisia’s

market capitalisation reflects that Promisia’s share price is trading at a 30.0% discount to Promisia’s

current NTA per share of $1.092.

Shareholder approval is also required under Listing Rule 5.2.1 by way of an ordinary resolution.

Listing Rule 5.2.1 provides that the Company must not enter into a Material Transaction if a Related

Party is, or is likely to become, a direct party to the Material Transaction, or a beneficiary of a

guarantee or other transaction which is a Material Transaction, unless that Material Transaction is

approved by an ordinary resolution of shareholders. Rhonda Sherriff is a Related Party of the

Company by virtue of being a director of the Company. The Acquisition constitutes a Material

Transaction because it involves the acquisition of assets with a gross value above 10% of Promisia's

Average Market Capitalisation. As Rhonda Sherriff is a direct party to the Material Transaction

(through the Sherriff Interest being a vendor), shareholder approval is required under Listing Rule

5.2.1.


16


Shareholder approval is also required under Listing Rule 4.2 as the issue of the Consideration Shares

is proposed to be made solely to the Sheriff Interest, an Associated Person of Rhonda Sherriff, a

director of Promisia. Accordingly, under Listing Rule 4.5.1(e)(ii), Promisia cannot issue the

Consideration Shares via its placement capacity and must seek shareholder approval. Shareholder

approval is also sought under Listing Rule 4.2 to approve the issue of the Convertible Notes.

For completeness, the Acquisition does not constitute a “major transaction” for the purposes of

section 129 of the Companies Act 1993.

Should shareholders not approve this Resolution, Promisia will not be able to proceed with the

Acquisition and will have to consider different investment opportunities. While there is no break fee

associated with the Acquisition, Promisia will have incurred significant sunk costs in having pursued

the Acquisition through legal fees, registry fees, regulatory fees and finance establishment charges.

It will also lose the opportunity to acquire what the Board consider to be a high quality asset that is a

strong strategic fit with Promisia on terms it considers likely to be value accretive to Promisia and

shareholders.

Waiver granted

Listing Rule 7.8.8(b) ordinarily requires an Appraisal Report to be prepared where a meeting of

shareholders will consider a resolution required by Listing Rule 5.2.1. NZ RegCo has granted Promisia

a waiver from this requirement.

Listing Rule 7.8.5(b) requires certain information to be provided to shareholders in connection with a

resolution to approve an issue of equity securities to a Related Party. Promisia has obtained a waiver

from NZ RegCo from Listing Rule 7.8.5(b).

A copy of NZ RegCo's waiver decision, including its reasons, was announced to market on 13 August

2026.

Non-Interested Director Recommendation

The Non-Interested Directors unanimously recommend that shareholders vote in favour of

Resolution 4 and certifies that in its opinion:

- The Share Issue is in the best interests of, and fair and reasonable to, Promisia and all non-

associated shareholders;

- The Acquisition is in the best interests of, and fair and reasonable to, Promisia and all non-

associated shareholders;

- The terms of the Acquisition (including the Purchase Price) were negotiated on an arm’s

length commercial basis;

- Promisia was not influenced to enter into the Acquisition by Rhonda Sherriff;

- The waivers are in the best interests of, and fair and reasonable to, Promisia and all non-

associated shareholders; and

- No inappropriate transfer of value is accruing to the Sherriff Interest as a consequence of the

Acquisition being a related party transaction.


The non-interested Directors reiterate that Rhonda Sherriff has not taken part in any of the Board’s

discussions or decisions regarding the Acquisition and has engaged in the Acquisition solely in her

capacity as a vendor, not as a director of the Company.


17


Resolution 5: Increase to the Directors Fee Pool

Resolution 5 seeks shareholder approval to increase the aggregate maximum annual amount of fees

that can be paid to Directors from $200,000 (Previous Fee Pool) to $350,000 (Proposed Fee Pool). If

the Proposed Fee Pool is approved, it will apply from 1 September 2026.

Directors and their Associated Persons are prohibited from voting on this Resolution 5.

Previous Fee Pool

The Previous Fee Pool was approved as a monetary sum per annum payable to all Directors of

Promisia taken together. At the time, Promisia had four directors. Under the Listing Rules, if the total

number of Directors subsequently increases, the Directors may, without a further shareholders

resolution, increase the director fee pool by such amount as is necessary to enable Promisia to pay

the average (non-Chair) director remuneration to the new director.

After the Previous Fee Pool was approved by shareholders, the number of directors on the Promisia

Board increased to five directors. Accordingly, the Previous Fee Pool automatically increased to

$245,000.

The Previous Fee Pool was allocated and paid amongst the current Board as follows:

Role Fee Pool Allocation

Chair of Board (x1) $75,000

Non-executive director (x3) $45,000

Executive Director (x1) Nil

Total $210,000


No additional fees are currently paid to Committee Chair’s or in respect of Committee memberships.

Executive Director

Tom Brankin became an executive director after the Previous Fee Pool was approved. Consequently,

he received $120,000 per annum in base remuneration for his executive role and ceased receiving

directors fees from the Director fee pool. As advised to the market earlier this year, Tom is ceasing

his executive services to Promisia from the time of the shareholders meeting and will then continue

in office as a non-executive director.

Accordingly, Resolution 5 is partly being put to shareholders to increase the capacity in the pool so

that there is capacity to pay Tom Brankin from the Director fee pool.

Market Review

In addition to ensuring the above capacity, approval of the Proposed Fee Pool is sought to ensure

that Promisia is paying its directors a market rate of directors’ fees that is sufficient to attract and

retain high-calibre directors. Factors supporting an increase to the Previous Fee Pool include:

- Inflation in the six years since the Previous Fee Pool was approved.


18


- Considerable growth in the scale and operations of Promisia, including:

o The acquisition of the Golden View and Ripponburn facilities in Cromwell.

o The acquisition of Aldwins House.

o Completion of the Ranfurly Manor villa expansion.

o Establishment of the Promisia support office and senior executive team.

- The strong improvement in financial performance by Promisia.

- Continued development and growth initiatives (including the Acquisition and development

opportunities remaining in the current facility portfolio) that place significant time demands

on the directors.

- The increased workload of Board sub-committees and the need to have capacity in the fee

pool to fairly remunerate directors for their workload in that regard. When the Previous Fee

Pool was approved, given the scale of Promisia at that time, much of the governance work

usually undertaken by committees was undertaken by the Board as a whole.

- In addition, special sub-committees may be set up from time to time to provide governance

oversight of specific initiatives in Promisia (such as redevelopments or acquisitions) and it

would be appropriate for the directors fee pool to have some capacity to pay additional fees

to directors where they are asked to invest additional time on key matters for Promisia that

drive value for shareholders.


The level of the Proposed Fee Pool was then determined with the Board having regard to:

- fees paid by other listed companies of a similar market capitalisation to Promisia.

- fees paid by other listed companies that operate in healthcare.

- the similarity in risk profile of those companies to Promisia.

- the expected further expansion of Promisia’s asset and operating base and the

corresponding expected increase in demands on the directors.

- The Institute of Directors 2025/26 Directors Fees Report which suggests that a general New

Zealand market median fee for a non-executive director is $53,700.


If approved the Board proposes to allocate the Proposed Fee Pool as follows:

Role Proposed annual fee

Chair of the Board $87,000

Non-executive directors (four directors at $54,000 per annum) $216,000

Risk, Audit and Assurance Committee Chair - Additional Fee $6,000

Contingency (special fees for sub-committee work or similar) $41,000

Total $350,000


Satisfying Directors Fees through Equity Securities

When the Previous Fee Pool was approved, shareholders also approved Promisia satisfying directors

fees through an issue of equity securities in accordance with Listing Rule 4.7. This flexibility will

remain if the Proposed Fee Pool is approved.


19


Listing Rule 4.7 only allows Promisia to issue equity securities to directors if:

• The equity securities are of a class already on issue;

• The issue of equity securities is made after the end of the period or half period to which that

remuneration is payable; and

• The issue price of the equity securities is not less than the ‘Average Market Price’ before the

issue occurs.



20


Appendix: Valuation letter from CBRE on Chatswood













N:\NZ-AKL-Vals_Health\Promisia\Chatswood\2026 06\Correspondence\2026 07 Chatswood Confirmation

Ltr.docx


CBRE Limited


Level 37, ANZ Centre

23-29 Albert Street

PO Box 2723

Auckland, New Zealand


T 64 9 355 3333

F 64 9 359 5430


www.cbre.co.nz

VVALUATION & ADVISORY SERVICES

27 July 2026



Promisia Healthcare Limited

919 Colombo Street

Christchurch 8013


Attention: Mr Francisco Rodriguez Ferrere



Confirmation of Value

Chatswood Retirement Village, 60 Hawford Road, Opawa, Christchurch



In accordance with instructions, we inspected the above complex on 21 July 2026 and have

completed a Market Valuation for potential acquisition purposes with an effective date of 31 July

2026.


We confirm we have assessed a value of $26,200,000 (Twenty Six Million, Two Hundred Thousand

Dollars) on the basis of a going concern and zero rated for GST, with land valued plus GST, if any.


We confirm that the valuers involved in the preparation of the valuation do not have any conflicts of

interest, nor any relationship with Promisia Healthcare Limited that would impair the objectivity or

independence of the valuer(s), or CBRE, when preparing the valuation.


We trust this meets your immediate requirements however we remain available to discuss further if

required.


Yours sincerely

CBRE Limited


Michael Gunn,

B.Com (VPM), SNZIV, MRICS

Registered Valuer

Senior Director – Retirement Housing & Healthcare

---

Go online to https://nz.investorcentre.mpms.mufg.com/voting/PHL to appoint your proxy

LODGE YOUR PROXY

















Proxy Form/Admission Card for Promisia Healthcare Limited 2026 Annual Shareholders’ Meeting


Notice is hereby given that the Annual Shareholders’ Meeting of Promisia Healthcare Limited (“the Company”) will be held at Duncan Cotterill, 148 Victoria

Street, Christchurch, Ōtautahi at 3pm (New Zealand time) on Thursday, 27 August 2026. If you will attend the Meeting, please bring this form to assist with

your registration.

Shareholders unable to attend in person may observe the meeting online at this link: Microsoft Teams Meeting


If you will not attend the meeting but wish to be represented by proxy, please complete and return this form (in accordance with the lodgment instructions

above) to Promisia Healthcare Limited’s share registry, MUFG Pension & Market Services, by no later than 3pm on Tuesday, 25 August 2026. You can

also appoint your proxy and vote on the resolutions on the reverse of this form online by going to https://nz.investorcentre.mpms.mufg.com/voting/PHL or

by scanning the QR code above with your smartphone.



Thursday, 27 August 2026 at 3:00pm (New Zealand time)

CSN/Holder Number: <CSN/Holder Number>


*Barcode*



Duncan Cotterill, 148 Victoria Street, Christchurch, Ōtautahi


Appointment of proxy

If you are entitled to vote at the meeting, you may appoint a proxy to attend

the meeting and vote on your behalf, unless specifically excluded. The

proxy need not also be a shareholder. If you wish, you may appoint any

director of the Company as your proxy or as alternative to your named

proxy. Each Director intends to vote all discretionary proxies in favour of the

relevant resolution however shareholders are encouraged to provide

express voting instructions on this form given the Chair is disqualified from

voting on Resolution 4 and all directors are disqualified from voting on

Resolution 5. Any discretionary proxies given to a director disqualified from

voting on a particular resolution will be disregarded.


Voting of your holding

Direct your proxy how to vote by making the appropriate election, either

online or on this Proxy Form, in respect of each resolution. If you return this

form without directing the proxy how to vote on any particular matter, the

proxy may vote as he/she thinks fit or abstain from voting. If you make more

than one election in respect of a resolution your vote will be invalid on that

resolution. If this Proxy Form is returned duly signed by a Shareholder with

voting instructions included, but without specifying a person that is

appointed as proxy, the Chair of the Meeting is deemed to be the proxy for

the purpose of that form, but only to vote to the extent of the voting

instructions provided.


Attending the meeting

If you plan to attend the meeting in person, please bring this Admission

Card/Proxy Form intact as the barcode will assist in your registration.


A corporation may appoint a person as its representative to attend and vote

at the Meeting in the same manner as that in which it could appoint a proxy.

That person need not also be a shareholder.

Signing instructions for this form

Individual

Where the holding is in one name, the shareholder must sign the Proxy

Form.


Joint Holding

Where the holding is in more than one name, at least one joint shareholder

should sign this form (on behalf of all joint shareholders). If different joint

shareholders purport to appoint different proxies, the vote of the proxy

appointed by the first named joint shareholder shall apply.


Power of Attorney

If this Proxy Form has been signed under a power of attorney, a copy of the

power of attorney under which it was signed (if not previously provided to

the Registrar), and a signed certificate of non-revocation of the power of

attorney must accompany this Proxy Form.


Corporate Shareholder

In the case of a corporate shareholder, a duly authorised officer or director

must sign this Proxy Form. Persons who sign on behalf of a corporate

shareholder must be acting with that corporate shareholder’s express or

implied authority.




Online

https://nz.investorcentre.mpms.mufg.com/voting/PHL


Scan & email

meetings.nz@cm.mpms.mufg.com

Scan this QR code with

your smartphone and vote

online



Mail

Use the enclosed reply paid

envelope or address to:

MUFG Pension & Market Services

PO Box 91976

Auckland 1142

General Enquiries


Email

enquiries.nz@cm.mpms.mufg.com


Phone

+64 9 375 5998

Space and position for name and address

Step 1 Appoint a Proxy / Corporate Representative

I/We being a shareholder/s of Promisia Healthcare Limited hereby appoint:


Name


or failing him/her:

Address


Name Address

As my/our proxy to vote for me/us on my/our behalf at the Annual Meeting of the Company to be held at 3pm on Thursday, 27 August 2026, and at any

adjournment of that Meeting.


Step 2 Items of Business – Voting Instructions


Instruct a proxy to vote by placing a tick in the relevant box. If you have appointed a proxy and want him/her to decide how to vote on the resolution, tick the

box “Proxy’s discretion”. Please note for each resolution you must tick one box.






Step 3 Shareholder Questions


Shareholders attending the Annual Shareholders’ Meeting will have the opportunity to ask questions during the meeting. If you cannot attend the Annual

Shareholders’ Meeting but would like to ask a question, you can submit a question online by going to https://nz.investorcentre.mpms.mufg.com/voting/PHL

and completing the online validation process or complete the question section below and return to MUFG Pension & Market Services in the envelope enclosed.

Questions will need to be submitted by 3pm on Tuesday, 25 August 2026. The Board will endeavour to address and answer questions at the Annual

Shareholders’ Meeting.


Question:


Step 4 Signature of Shareholder(s) This section must be completed



Shareholder 1

or duly authorised officer or attorney


Shareholder 2

or duly authorised officer or attorney


Shareholder 3

or duly authorised officer or attorney



Contact Name


Contact Daytime Telephone


Date

Electronic Investor Communications

If you received the Notice of Meeting and Proxy Form by mail and wish to receive your future investor communications by email please provide your email

address below:



To consider and, if thought fit, pass the following ordinary resolutions:

FOR AGAINST ABSTAIN

PROXY

DISCRETION

1. 1. To authorise the directors to fix the auditor’s remuneration for the ensuing year.




2. 2. That Craig Percy, who retires by rotation and is eligible for re-election, be re-elected as a

director of Promisia.


3. 3. That Rhonda Sherriff, who retires by rotation and is eligible for re-election, be re-elected as

a director of Promisia.


4. 4. That Promisia undertaking the Acquisition under Listing Rule 5.1.1 (major transaction),

5.2.1 (related party transaction) and Rule 4.2.1 (issue of new equity securities) and on the

terms more fully set out in the explanatory notes, is approved.


5. 5. That under Listing Rule 2.11.1 (directors’ remuneration) the Board is authorised to increase

the aggregate maximum annual amount of fees that can be paid to Directors from $200,000

approved in 2020 to $350,000, with such increase taking effect on 1 September 2026.


CSN/Holder Number: 123456789


*Barcode*

Data sourced from publicly available filings. Our datasets may not be complete. Automated analysis can produce errors. If you believe any data on this page is incorrect, please contact us at hello@nzxplorer.co.nz. For informational purposes only. Not investment advice.